Boehringer Ingelheim disclosed discovery of novel cyclic GMP‑AMP synthase (cGAS) inhibitors argued to be useful across a spectrum of inflammatory and fibrotic indications, from autoinflammatory interferonopathy to idiopathic pulmonary fibrosis and systemic lupus erythematosus. The company’s preclinical disclosure outlines chemical series and proposed therapeutic applications, positioning Boehringer to pursue small‑molecule immunomodulators targeting innate immune sensing.